ERBB2 and neoplasm: Recently, however, HER2-based antibody–drug conjugates (ADCs) have been developed that, unlike traditional anti-HER2 monoclonal antibodies, can be effective in tumours that lack strong oncogenic addiction to HER2 but have lower levels of HER2 expression.7